Role of complement activation in atherosclerosis

Current Opinion in Lipidology

Volumn 14, Issue 5, 2003, Pages 477-482

  Oksjoki, Riina ^a   Kovanen, Petri T ^a   Pentikäinen, Markku O ^a  

^a WIHURI RESEARCH INSTITUTE   (Finland)

Author keywords

Atherosclerosis; Complement; Inflammation

Indexed keywords

ANAPHYLATOXIN; ANAPHYLATOXIN C3B; ANAPHYLATOXIN IC3B; C REACTIVE PROTEIN; CHOLESTEROL; COMPLEMENT; LIPOPROTEIN; RECEPTOR; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ADVENTITIA; ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; ARTERY INTIMA; ARTERY MEDIA; ATHEROGENESIS; ATHEROSCLEROSIS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CRYSTAL; DISEASE SEVERITY; ENDOTHELIUM CELL; EXPERIMENT; EXPERIMENTAL MODEL; GENETIC ENGINEERING; HUMAN; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; ARTERIOSCLEROSIS; C-REACTIVE PROTEIN; CHOLESTEROL; COMPLEMENT ACTIVATION; COMPLEMENT C3B; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT SYSTEM PROTEINS; HUMANS; INFLAMMATION; LIPOPROTEINS; MODELS, ANIMAL; TUNICA INTIMA;

EID: 0142093142     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200310000-00008     Document Type: Review

References (63)

1. Niculescu F, Rus H. Complement activation and atherosclerosis. Mol Immunol 1999; 36:949-955.
2. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158:1039-1051.
3. Vlaicu R, Niculescu F, Rus HG, Cristea A. Immunohistochernical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis 1985; 57:163-177.
4. Torzewski M, Torzewski J, Bowyer DE, et al. Immunohistochemical colocalization of the terminal complex of human complement and smooth muscle cell alpha-actin in early atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1997; 17:2448-2452.
5. Rus HG, Niculescu F, Constantinescu E, et al. Immunoelectron-microscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque. Atherosclerosis 1986; 61:35-42.
6. Torzewski M, Klouche M, Hock J, et al. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol 1998; 18:369-378.
7. Seifert PS, Hugo F, Hansson GK, Bhakdi S. Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab Invest 1989; 60:747-754.
8. Laine P, Pentikainen MO, Wurzner R, et al. Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction. Am J Cardiol 2002; 90:404-408. This paper demonstrates increased amounts of iC3b in ruptured and vulnerable atherosclerotic plaques, suggesting a role for complement activation in acute coronary syndromes.
9. Hammerschmidt DE, Greenberg CS, Yamada O, et al. Cholesterol and atheroma lipids activate complement and stimulate granulocytes. A possible mechanism for amplification of ischemic injury in atherosclerotic states. J Lab Clin Med 1981; 98:68-77.
10. Ji H, Ohmura K, Mahmood U, et al. Arthritis critically dependent on innate immune system players. Immunity 2002; 16:157-168.
11. Vlaicu R, Rus HG, Niculescu F, Cristea A. Quantitative determinations of immunoglobulins and complement components in human aortic atherosclerotic wall. Med Interne 1985; 23:29-35.
12. Yla-Herttuala S, Palinski W, Butler SW, et al. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994; 14:32-40.
13. Jarva H, Jokiranta TS, Hellwage J, et al. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol 1999; 163:3957-3962.
14. Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18:1386-1392.
15. Reynolds GD, Vance RP. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med 1987; 111:265-269.
16. Oksjoki R, Jarva H, Kovanen PT, et al. Association between complement factor H and proteoglycans in early human coronary atherosclerotic lesions: implications for local regulation of complement activation. Arterioscler Thromb Vasc Biol 2003; 23:630-636. This paper demonstrates different staining patterns for complement components C3d and C5b-9 and the association of C3d, proteoglycans, and factor H, which, together with in-vitro experiments, suggest the active regulation of complement by factor H in atherosclerotic lesions.
17. de Beer FC, Soutar AK, Baltz ML, et al. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med 1982; 156:230-242.
18. Taskinen S, Kovanen PT, Jarva H, et al. Binding of C-reactive protein to modified low-density lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein. Biochem J 2002; 367:403-412.
19. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999; 19:2348-2354.
20. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A 2002; 99:13043-13048.
21. Bodman-Smith KB, Melendez AJ, Campbell I, et al. C-reactive protein-mediated phagocytosis and phospholipase D signalling through the high-affinity receptor for immunoglobulin G (FcgammaRI). Immunology 2002; 107:252-260.
22. Rolph MS, Zimmer S, Bottazzi B, et al. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002; 22:e10-e14.
23. Seifert PS, Hugo F, Tranum-Jensen J, et al. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med 1990; 172:547-557.
24. Bhakdi S, Dorweiler B, Kirchmann R, et al. On the pathogenesis of atherosclerosis; enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med 1995; 182:1959-1971.
25. Seifert PS, Kazatchkine MD. Generation of complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position. Mol Immunol 1987; 24:1303-1308.
26. Seifert PS, Hansson GK. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis 1989; 9:802-811.
27. Yasojima K, Schwab C, McGeer EG, McGeer PL. Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21:1214-1219.
28. Seifert PS, Roth I, Schmiedt W, et al. CD59 (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9 attack, in human atherosclerotic lesions. Atherosclerosis 1992; 96:135-145.
29. Bhakdi S, Roth M. Fluid-phase SC5b-8 complex of human complement: generation and isolation from serum. J Immunol 1981; 127:576-580.
30. Niculescu F, Rus HG, Porutiu D, et al. Immunoelectron-microscopic localization of S-protein/vitronectin in human atherosclerotic wall. Atherosclerosis 1989; 78:197-203.
31. Niculescu F, Rus HG, Vlaicu R. Activation of the human terminal complement pathway in atherosclerosis. Clin Immunol Immunopathol 1987; 45:147-155.
32. Saito E, Fujioka T, Kanno H, et al. Complement receptors in atherosclerotic lesions. Artery 1992; 19:47-62.
33. Mevorach D, Mascarenhas JO, Gershov D, Elkon KB. Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 1998; 188:2313-2320.
34. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 1999; 17:593-623.
35. Husemann J, Obstfeld A, Febbraio M, et al. CD11b/CD18 mediates production of reactive oxygen species by mouse and human macrophages adherent to matrixes containing oxidized LDL. Arterioscler Thromb Vasc Biol 2001; 21:1301-1305.
36. Niculescu F, Rus H. Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells. Immunol Res 2001; 24:191-199.
37. Seeger W, Suttorp N, Hellwig A, Bhakdi S. Noncytolytic terminal complement complexes may serve as calcium gates to elicit leukotriene B4 generation in human polymorphonuclear leukocytes. J Immunol 1986; 137:1286-1293.
38. Niculescu F, Rus H, Shin ML. Receptor-independent activation of guanine nucleotide-binding regulatory proteins by terminal complement complexes. J Biol Chem 1994; 269:4417-4423.
39. Kilgore KS, Schmid E, Shanley TP, et al. Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol 1997; 150:2019-2031.
40. Torzewski J, Oldroyd R, Lachmann P, et al. Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol 1996; 16:673-677.
41. Niculescu F, Badea T, Rus H. Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. Atherosclerosis 1999; 142:47-56.
42. Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 1994; 179:985-992.
43. Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989; 264:9053-9060.
44. Tedesco F, Pausa M, Nardon E, et al. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997; 185:1619-1627.
45. Kilgore KS, Shen JP, Miller BF, et al. Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol 1995; 155:1434-1441.
46. Arend WP, Massoni RJ, Niemann MA, Giclas PC. Absence of induction of IL-1 production in human monocytes by complement fragments. J Immunol 1989; 142:173-178.
47. Murakami Y, Imamichi T, Nagasawa S. Characterization of C3a anaphylatoxin receptor on guinea-pig macrophages. Immunology 1993; 79:633-638.
48. Takabayashi T, Vannier E, Clark BD, et al. A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis. J Immunol 1996; 156:3455-3460.
49. Takabayashi T, Vannier E, Burke JF, et al. Both C3a and C3a(desArg) regulate interleukin-6 synthesis in human peripheral blood mononuclear cells. J Infect Dis 1998; 177:1622-1628.
50. Nataf S, Davoust N, Ames RS, Barnum SR. Human T cells express the C5a receptor and are chemoattractecl to C5a. J Immunol 1999; 162:4018-4023.
51. Schulman ES, Post TJ, Henson PM, Giclas PC. Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release. J Clin Invest 1988; 81:918-923.
52. Foreman KE, Vaporciyan AA, Bonish BK, et al. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 1994; 94:1147-1155.
53. Okusawa S, Yancey KB, van der Meer JW, et al. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. J Exp Med 1988; 168:443-448.
54. McCarthy K, Henson PM. Induction of lysosomal enzyme secretion by alveolar macrophages in response to the purified complement fragments C5a and C5a des-arg. J Immunol 1979; 123:2511-2517.
55. Morgan EL, Thoman ML, Weigle WO, Hugli TE. Anaphylatoxin-mediated regulation of the immune response. II. C5a-mediated enhancement of human humoral and T cell-mediated immune responses. J Immunol 1983; 130:1257-1261.
56. Baumann U, Chouchakova N, Gewecke B, et al. Distinct tissue site-specific requirements of mast cells and complement components C3/C5a receptor in IgG immune complex-induced injury of skin and lung. J Immunol 2001; 167:1022-1027. See Ref. [57••].
57. Shushakova N, Skokowa J, Schulman J, et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Invest 2002; 110:1823-1830. These papers demonstrate an important novel function of C5a-C5aR signaling in mast cells and macrophages also with potential importance in atherosclerosis.
58. Geertinger P, Sorensen H. Complement as a factor in arteriosclerosis. Acta Pathol Microbiol Scand [A] 1970; 78:284-288.
59. Geertinger P, Sorensen H. On the reduced atherogenic effects of cholesterol feeding on rabbits with congenital complement (C6) deficiency. Artery 1977; 1:177-184.
60. Schmiedt W, Kinscherf R, Deigner HP, et al. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1998; 18:1790-1795.
61. Saito E, Mitsui E, Fujioka T, et al. Effect of K-76 COONa, an anticomplementary agent, on experimental atherosclerosis in rabbits. J Drug Dev 1990; 3 (Suppl.):147-154.
62. Patel S, Thelander EM, Hernandez M, et al. ApoE(-/-) mice develop atherosclerosis in the absence of complement component CS. Biochem Biophys Res Commun 2001; 286:164-170.
63. -/- mice, although the lesions were similar in size.